Description

Simple

Clinical

Overview

Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children. Vayarin contains _Lipirinen_, a proprietary composition containing phosphatidylserine-omega 3, EPA (eicosapentaenoic acid), and docosahexaenoic acid (DHA) [5, L14501, 13]. Vayarin is currently available only by prescription in the USA [7]. This drug has also been used for management of hypertriglyceridemia [8].

Vayarin is an orally administered prescription medical food for the clinical dietary management of complex lipid imbalances thought to be associated with ADHD. Vayarin is a specially formulated and designed to address the distinct, previously determined lipid nutritional requirements of children with ADHD, the dietary management of which cannot be achieved with lifestyle modification [<... Read more

Pharmacology

Indication

ADHD in children, hypertriglyceridemia [7, Read more

Pharmacodynamic

Compared to healthy children of the same age, children with ADHD have lower circulating concentrations of omega-3 long-chain polyunsaturated fatty acid. These lipids, found in the brain, play an essential role in central nervous system development and function. It has been reported that omega-3 fatt... Read more

Mechanism of action

Phosphatidylserine (PS) in the mammalian nervous system, containing high levels of omega-3 fatty acids, has been implicated in numerous membrane-associated functions, such as maintaining the integrity of cell membranes, cell excitability and cell-to-cell recognition and communication. While the exac... Read more

Absorption

Phosphatidylserine (the main component of this medical food) is an endogenous substance found in the human body. This medication is metabolized mainly in the intestines by decarboxylases in the mucosal cells [10]. Th... Read more

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Mainly in the feces and urine [10].

Half life

About 2h [11]

Route of elimination

For all routes of administration, about 60% of the ingested PS is excreted in feces, while 10% is eliminated in the urine [10].

Toxicity

The safety phosphatidyl serine conjugated to omega-3 (PS-Omega-3) is supported by several pre-clinical studies. Multiple dose safety studies in rats and dogs showed that oral administration of PS-Omega-3 at doses up to 1000 mg/kg/day for up to 6 months was without any significant effects. Teratogeni... Read more

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vayarin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Acetaminophen
Vayarin may increase the hepatotoxic activities of Acetaminophen.
Aniline
The metabolism of Aniline can be decreased when combined with Vayarin.
Benzyl alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Vayarin.
Carvedilol
The metabolism of Carvedilol can be decreased when combined with Vayarin.
Cenobamate
The metabolism of Cenobamate can be decreased when combined with Vayarin.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Vayarin.
Enflurane
The metabolism of Enflurane can be decreased when combined with Vayarin.
Ethanol
The metabolism of Ethanol can be decreased when combined with Vayarin.
Ethosuximide
The metabolism of Ethosuximide can be decreased when combined with Vayarin.
Felbamate
The metabolism of Felbamate can be decreased when combined with Vayarin.
Fingolimod
The metabolism of Fingolimod can be decreased when combined with Vayarin.
Halothane
The metabolism of Halothane can be decreased when combined with Vayarin.
Isoflurane
The metabolism of Isoflurane can be decreased when combined with Vayarin.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Vayarin.
Nilvadipine
The metabolism of Nilvadipine can be decreased when combined with Vayarin.
Phenytoin
The metabolism of Phenytoin can be decreased when combined with Vayarin.
Propacetamol
Vayarin may increase the hepatotoxic activities of Propacetamol.
Quinidine
The metabolism of Quinidine can be decreased when combined with Vayarin.
Sevoflurane
The metabolism of Sevoflurane can be decreased when combined with Vayarin.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Vayarin.
13 References
  1. 1 . Hamilton L, Greiner R, Salem N Jr, Kim HY: n-3 fatty acid deficiency decreases phosphatidylserine accumulation selectively in neuronal tissues. Lipids. 2000 Aug;35(8):863-9.PubMed: 10984109
  2. 2 . Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A: Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry. 2013 Aug;28(6):386-91. doi: 10.1016/j.eurpsy.2012.11.001. Epub 2013 Jan 9.PubMed: 23312676
  3. 3 . Mozzi R, Buratta S, Goracci G: Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res. 2003 Feb;28(2):195-214.PubMed: 12608694
  4. 4 . WISE EM Jr, ELWYN D: RATES OF REACTIONS INVOLVED IN PHOSPHATIDE SYNTHESIS IN LIVER AND SMALL INTESTINE OF INTACT RATS. J Biol Chem. 1965 Apr;240:1537-48.PubMed: 14285489
  5. 5 . Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Link
  6. 6 . Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment (VAYA-fMRI) Link
  7. 7 . mproved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study Link
  8. 8 . Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion Link
  9. 9 . Vaya Direct Link
  10. 10 . Vayarin product label Link
  11. 11 . FDA label PS Link
  12. 12 . Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA Link
  13. 13 . Drug Insert Vayarin Link